Preferences of people living with HIV for injectable and oral antiretroviral treatment in the Netherlands: a discrete choice experiment

AIDS Care. 2024 Apr;36(4):536-545. doi: 10.1080/09540121.2023.2240067. Epub 2023 Aug 1.

Abstract

ABSTRACTInjectable antiretroviral treatment (ART) represents a new effective and potentially more convenient alternative to oral ART for people living with HIV (PLWH). This study assessed preferences of PLWH for long-acting injectable compared with oral ART in the Netherlands. A labelled discrete choice experiment presented 12 choice sets of long-acting injectable and oral ART. PLWH were asked to select their preferred ART, described by six attributes: location of administration, dosing frequency, risk of short-term side effects, drug-drug interaction, forgivability, and food and mealtime restrictions. Random parameters logit and latent class models were used to estimate preferences of PLWH. 98.6% of 76 respondents were experienced oral ART users that had taken ART for a median of 12 years (Q1-Q3: 7.0-20.0). 30 (39.5%) respondents chose long-acting injectable ART in all choice tasks and 22 (28.9%) always chose oral ART. The random parameter model showed that, on average, respondents significantly favoured long-acting injectable ART over oral ART, preferred administration of the long-acting injectable ART at home, and a less frequent regimen. The latent class model confirmed one class strongly preferring long-acting injectable ART and one class slightly preferring oral ART. This study highlights the value for both long-acting injectable and oral ART.

Keywords: Antiretroviral therapy; discrete choice experiment; long-acting injectable; oral therapy; people living with HIV; preferences.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Retroviral Agents / therapeutic use
  • HIV Infections* / drug therapy
  • Humans
  • Netherlands
  • Patient Preference
  • Surveys and Questionnaires

Substances

  • Anti-Retroviral Agents